Pharmaust Limited (AU:NUZ)

ASX:NUZ

NUZ

Pharmaust Limited

RESEARCH TOOLSreports

Want to see AU:NUZ full AI Analyst Report?

Pharmaust Limited (NUZ) Price & Analysis

28 Followers

NUZ Stock Chart & Stats

AU$0.10

AU$0.00(0.00%)

At close: Jan 08 4:00 PM EST

AU$0.10

AU$0.00(0.00%)

Day’s Range― - ―

52-Week RangeAU$0.06 - AU$0.18

Previous CloseN/A

Volume246.69K

Average Volume (3M)1.10M

Market Cap

AU$47.50M

Enterprise ValueAU$47.11M

Total Cash (Recent Filing)AU$9.72M

Total Debt (Recent Filing)AU$0.00

Price to Earnings (P/E)―

Beta1.28

Next Earnings

Aug 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.02

Shares Outstanding753,982,670

10 Day Avg. Volume1,596,000

30 Day Avg. Volume1,096,098

Financial Highlights & Ratios

PEG Ratio-0.08

Price to Book (P/B)25.24

Price to Sales (P/S)0.00

P/FCF Ratio-4.98

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$0.20

Price Target Upside100.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low LeverageReported zero total debt materially reduces refinancing and interest-burden risk over the next few quarters. This durable balance-sheet feature preserves flexibility for restructuring, fundraising timing, or strategic partnerships without immediate debt-servicing constraints.

Cash Losses Track AccountingOperating and free cash flow move roughly in line with net losses, indicating accounting losses reflect real cash consumption rather than timing or working-capital distortions. That transparency improves forecasting reliability and long-term planning for cost reduction or financing.

Historic Commercial RevenueThe company generated multi-year revenue recently, evidencing prior commercial capability or market access. That historical revenue base is a durable asset: it implies existing product/partner experience and a clearer pathway to re‑monetisation if R&D or commercial programs are reactivated.

Bears Say

Zero Revenue In 2025A complete loss of revenue is a structural impairment to business sustainability: fixed costs and R&D remain but there is no operating income to offset them. Over a multi‑quarter horizon this increases reliance on external funding and stresses long‑term viability.

Accelerating Cash BurnCash outflows have more than doubled year‑over‑year, sharply increasing financing needs and shortening runway. Persistent, accelerating burn elevates dilution risk, forces priority on capital availability, and constrains ability to invest in development or commercialization.

Rapid Equity ErosionSevere drop in shareholder equity erodes the capital buffer, reducing borrowing capacity and increasing the likelihood of dilutive recapitalisation. It signals returns are negative and that existing shareholders have been materially consumed by operating losses.

Pharmaust Limited News

Neurizon Therapeutics Seeks ASX Quotation for 9.7 Million New Shares

Pharmaust Limited ( ($AU:NUZ) ) has issued an announcement. Neurizon Therapeutics Limited has applied for quotation on the...

6h ago

Neurizon Secures Long-Term Elanco Supply Deal for Lead ALS Drug NUZ-001

Pharmaust Limited ( ($AU:NUZ) ) just unveiled an update. Neurizon Therapeutics has signed a long-term supply agreement with...

2d ago

Neurizon Therapeutics Seeks ASX Quotation for 7.7 Million New Shares

The latest update is out from Pharmaust Limited ( ($AU:NUZ) ). Neurizon Therapeutics Limited has applied to the...

17d ago

Neurizon expands HEALEY ALS trial cohort and outlines strategy for NUZ-001

Pharmaust Limited ( ($AU:NUZ) ) just unveiled an announcement. Neurizon Therapeutics will host a webinar to outline the...

22d ago

Neurizon Expands HEALEY ALS Trial Regimen to 240 Patients Without Raising Funding Needs

Pharmaust Limited ( ($AU:NUZ) ) has issued an update. Neurizon Therapeutics will expand Regimen I of the HEALEY...

23d ago

Neurizon Wins Ethics Approval for Phase 1 NUZ-001 Oral Liquid Study

The latest update is out from Pharmaust Limited ( ($AU:NUZ) ). Neurizon Therapeutics has secured ethics approval from...

1M ago

Neurizon Therapeutics Discloses Director Departure and Remaining Equity Interests

Pharmaust Limited ( ($AU:NUZ) ) has issued an update. Neurizon Therapeutics Limited has announced the cessation of Dr...

1M ago

Neurizon Therapeutics appoints Dr Ross Murdoch as new director

The latest announcement is out from Pharmaust Limited ( ($AU:NUZ) ). Neurizon Therapeutics Limited has appointed Dr Ross...

1M ago

Neurizon Targets Investor Visibility with NUZ-001 ALS Update at Microcap Conference

Pharmaust Limited ( ($AU:NUZ) ) has provided an announcement. Neurizon Therapeutics will present at the 15th Annual Australian...

1M ago

Neurizon steps up investor outreach with NUZ-001 ALS briefing series

Pharmaust Limited ( ($AU:NUZ) ) has shared an announcement. Neurizon Therapeutics has launched a series of in-person investor...

2M ago

NUZ FAQ

What was Pharmaust Limited’s price range in the past 12 months?

Pharmaust Limited lowest share price was AU$0.06 and its highest was AU$0.18 in the past 12 months.

What is Pharmaust Limited’s market cap?

Pharmaust Limited’s market cap is AU$47.50M.

When is Pharmaust Limited’s upcoming earnings report date?

Pharmaust Limited’s upcoming earnings report date is Aug 27, 2026 which is in 69 days.

How were Pharmaust Limited’s earnings last quarter?

Pharmaust Limited released its earnings results on Feb 24, 2026. The company reported -AU$0.011 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.011.

Is Pharmaust Limited overvalued?

According to Wall Street analysts Pharmaust Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Pharmaust Limited pay dividends?

Pharmaust Limited does not currently pay dividends.

What is Pharmaust Limited’s EPS estimate?

Pharmaust Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Pharmaust Limited have?

Pharmaust Limited has 753,982,670 shares outstanding.

What happened to Pharmaust Limited’s price movement after its last earnings report?

Pharmaust Limited reported an EPS of -AU$0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.031%.

Which hedge fund is a major shareholder of Pharmaust Limited?

Currently, no hedge funds are holding shares in AU:NUZ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Pharmaust Limited Stock Smart Score

Outperform

Fundamentals

Return on Equity

-254.33%

Trailing 12-Months

Asset Growth

-6.22%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Pharmaust Limited

Neurizon Therapeutics Limited, a clinical-stage biotechnology company established in 2000 and headquartered in Melbourne, Australia, focuses on pioneering treatments for neurodegenerative diseases. The firm actively creates intellectual property through its endeavors in discovering novel drugs for neurological conditions. Its leading experimental therapeutic, NUZ-001, is a small molecule compound presently in Phase II clinical trials. This candidate is being evaluated for its effectiveness against amyotrophic lateral sclerosis (ALS) and various other neurodegenerative disorders. The company, formerly named PharmAust Limited, officially transitioned to Neurizon Therapeutics Limited in October 2024.

Pharmaust Limited (NUZ) Earnings & Revenues

Historic Earnings Reports

NUZ Stock 12 Month Forecast

Average Price Target

AU$0.20

▲(100.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"AU$0","1":"AU$1","-1":"-AU$1","-0.5":"-AU$0.5","0.5":"AU$0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$0.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$0.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$0.20</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.065,0.07538461538461538,0.08576923076923076,0.09615384615384616,0.10653846153846154,0.11692307692307692,0.12730769230769232,0.1376923076923077,0.14807692307692308,0.15846153846153846,0.16884615384615384,0.17923076923076925,0.18961538461538463,{"y":0.2,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.065,0.07538461538461538,0.08576923076923076,0.09615384615384616,0.10653846153846154,0.11692307692307692,0.12730769230769232,0.1376923076923077,0.14807692307692308,0.15846153846153846,0.16884615384615384,0.17923076923076925,0.18961538461538463,{"y":0.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.065,0.07538461538461538,0.08576923076923076,0.09615384615384616,0.10653846153846154,0.11692307692307692,0.12730769230769232,0.1376923076923077,0.14807692307692308,0.15846153846153846,0.16884615384615384,0.17923076923076925,0.18961538461538463,{"y":0.2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.137,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.152,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.167,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.152,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.122,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.113,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.103,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.085,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.09,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.09,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.078,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.083,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.065,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >